255 related articles for article (PubMed ID: 32977539)
61. Structure-function relationships of autotaxin, a secreted lysophospholipase D.
Hausmann J; Perrakis A; Moolenaar WH
Adv Biol Regul; 2013 Jan; 53(1):112-7. PubMed ID: 23069371
[TBL] [Abstract][Full Text] [Related]
62. Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature.
Castagna D; Budd DC; Macdonald SJ; Jamieson C; Watson AJ
J Med Chem; 2016 Jun; 59(12):5604-21. PubMed ID: 26745766
[TBL] [Abstract][Full Text] [Related]
63. New insights into the autotaxin/LPA axis in cancer development and metastasis.
Leblanc R; Peyruchaud O
Exp Cell Res; 2015 May; 333(2):183-189. PubMed ID: 25460336
[TBL] [Abstract][Full Text] [Related]
64. Structure-based discovery of (S)-2-amino-6-(4-fluorobenzyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione as low nanomolar, orally bioavailable autotaxin inhibitor.
Roy A; Sarkar T; Datta S; Maiti A; Chakrabarti M; Mondal T; Mondal C; Banerjee A; Roy S; Mukherjee S; Muley P; Chakraborty S; Banerjee M; Kundu M; Roy KK
Chem Biol Drug Des; 2022 Mar; 99(3):496-503. PubMed ID: 34951520
[TBL] [Abstract][Full Text] [Related]
65. A 3D view of autotaxin.
Nishimasu H; Ishitani R; Aoki J; Nureki O
Trends Pharmacol Sci; 2012 Mar; 33(3):138-45. PubMed ID: 22277299
[TBL] [Abstract][Full Text] [Related]
66. Pleotropic Roles of Autotaxin in the Nervous System Present Opportunities for the Development of Novel Therapeutics for Neurological Diseases.
Herr DR; Chew WS; Satish RL; Ong WY
Mol Neurobiol; 2020 Jan; 57(1):372-392. PubMed ID: 31364025
[TBL] [Abstract][Full Text] [Related]
67. Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling.
Keune WJ; Hausmann J; Bolier R; Tolenaars D; Kremer A; Heidebrecht T; Joosten RP; Sunkara M; Morris AJ; Matas-Rico E; Moolenaar WH; Oude Elferink RP; Perrakis A
Nat Commun; 2016 Apr; 7():11248. PubMed ID: 27075612
[TBL] [Abstract][Full Text] [Related]
68. Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
Farquhar MJ; Humphreys IS; Rudge SA; Wilson GK; Bhattacharya B; Ciaccia M; Hu K; Zhang Q; Mailly L; Reynolds GM; Ashcroft M; Balfe P; Baumert TF; Roessler S; Wakelam MJO; McKeating JA
J Hepatol; 2017 May; 66(5):919-929. PubMed ID: 28126468
[TBL] [Abstract][Full Text] [Related]
69. Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate.
Benesch MG; Zhao YY; Curtis JM; McMullen TP; Brindley DN
J Lipid Res; 2015 Jun; 56(6):1134-44. PubMed ID: 25896349
[TBL] [Abstract][Full Text] [Related]
70. Characterization of non-lipid autotaxin inhibitors.
Hoeglund AB; Howard AL; Wanjala IW; Pham TC; Parrill AL; Baker DL
Bioorg Med Chem; 2010 Jan; 18(2):769-76. PubMed ID: 20005724
[TBL] [Abstract][Full Text] [Related]
71. Identifying Novel ATX Inhibitors via Combinatory Virtual Screening Using Crystallography-Derived Pharmacophore Modelling, Docking Study, and QSAR Analysis.
Ren JX; Zhang RT; Zhang H
Molecules; 2020 Mar; 25(5):. PubMed ID: 32131468
[TBL] [Abstract][Full Text] [Related]
72. Structural and PK-guided identification of indole-based non-acidic autotaxin (ATX) inhibitors exhibiting high in vivo anti-fibrosis efficacy in rodent model.
Lei H; Cao Z; Wu H; Li T; Wang X; Chen Y; Ma E; Sun L; Zhai X
Eur J Med Chem; 2022 Jan; 227():113951. PubMed ID: 34742015
[TBL] [Abstract][Full Text] [Related]
73. Signalling by lysophosphatidate and its health implications.
Hemmings DG; Brindley DN
Essays Biochem; 2020 Sep; 64(3):547-563. PubMed ID: 32451553
[TBL] [Abstract][Full Text] [Related]
74. Autotaxin and LPA receptor signaling in cancer.
Houben AJ; Moolenaar WH
Cancer Metastasis Rev; 2011 Dec; 30(3-4):557-65. PubMed ID: 22002750
[TBL] [Abstract][Full Text] [Related]
75. Design and Development of Autotaxin Inhibitors.
Jia Y; Li Y; Xu XD; Tian Y; Shang H
Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832985
[TBL] [Abstract][Full Text] [Related]
76. Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis.
Bain G; Shannon KE; Huang F; Darlington J; Goulet L; Prodanovich P; Ma GL; Santini AM; Stein AJ; Lonergan D; King CD; Calderon I; Lai A; Hutchinson JH; Evans JF
J Pharmacol Exp Ther; 2017 Jan; 360(1):1-13. PubMed ID: 27754931
[TBL] [Abstract][Full Text] [Related]
77. Development of an activity-based probe for autotaxin.
Cavalli S; Houben AJ; Albers HM; van Tilburg EW; de Ru A; Aoki J; van Veelen P; Moolenaar WH; Ovaa H
Chembiochem; 2010 Nov; 11(16):2311-7. PubMed ID: 20941725
[TBL] [Abstract][Full Text] [Related]
78. [Clinical introduction of lysophosphatidic acid and autotaxin assays].
Yatomi Y
Rinsho Byori; 2010 Jun; 58(6):631-5. PubMed ID: 20662276
[TBL] [Abstract][Full Text] [Related]
79. Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis.
Bai Z; Cai L; Umemoto E; Takeda A; Tohya K; Komai Y; Veeraveedu PT; Hata E; Sugiura Y; Kubo A; Suematsu M; Hayasaka H; Okudaira S; Aoki J; Tanaka T; Albers HM; Ovaa H; Miyasaka M
J Immunol; 2013 Mar; 190(5):2036-48. PubMed ID: 23365076
[TBL] [Abstract][Full Text] [Related]
80. Genetic deletion of Autotaxin from CD11b+ cells decreases the severity of experimental autoimmune encephalomyelitis.
Ninou I; Sevastou I; Magkrioti C; Kaffe E; Stamatakis G; Thivaios S; Panayotou G; Aoki J; Kollias G; Aidinis V
PLoS One; 2020; 15(4):e0226050. PubMed ID: 32240164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
